Erratum to ERG report: Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systematic treatment - Addendum to Evidence Review Group's Report following Pfizer's submission addendum post appeal dated 8 October 2013

Corrections are in red and **bold (in the bottom right cell only)**:

Table 5: Summary of results (Axitinib versus pazopanib in prior-cytokine population)

VEG105192	**Pazopanib**	**Placebo**	**Difference**	**HR (95% CI)**
Median PFS (months)	7.4	4.2	3.2	0.54 (0.35 to 0.84)
Median OS (months)	22.7	18.7	4.0	0.82 (0.57 to 1.16) ITT 0.53 (0.315 to 1.112) IPCW 0.53 (0.341 to 4.849) RPSFT
Indirect comparison	**Axitinib**	**Pazopanib**	**Difference**	**HR (95% CrI)**
Median PFS (months)	11.5*	7.4*	4.1*	0.465 (0.255 to 0.852)
Median OS (months)	33.3*	22.7*	10.6*	0.77 (**0.44 to 1.38**) ITT** 1.197 (**0.55 to 2.61**) IPCW** **1.208 (0.30 to 4.82)** RPSFT**

HR=Hazard Ratio; ITT=Intention-to-Treat; IPCW=inverse probability of censor weighting; RPSFT=rank preserving structural failure time

* See Table 12, Pfizer's submission addendum post appeal (A copy of this table is added as Appendix 1 in this report)

** ERG calculations